YACHT-CLUB-DE-MONACO
24.7.2024 17:10:27 CEST | Business Wire | Press release
As the curtain fell on the 11th Monaco Energy Boat Challenge, combining Tech Talks and on-water contests that saw 40 universities and 450 students from 25 nations showcasing their progress in alternative propulsion technology, Yacht Club de Monaco continues to support innovation in pursuit of sustainability in the yachting sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724805334/en/
Design, innovate and build an ecosystem that invests in green solutions. ©Mesi / YCM
“Preserving the environment is at the heart of what most concerns us. Protecting our planet’s rich yet fragile marine ecosystem is our top priority. If you want to raise the bar, you have to become an agent of change,” says YCM President, HSH Prince Albert II of Monaco, when outlining the roadmap.
This commitment is reflected in the SEA Index®, a benchmark measuring the environmental impact of yachts (+25m), available to owners and shipyards, and is now applied in 15 harbors and marinas from Menton to Saint-Tropez, Corsica, and those operated by SEPM in Monaco.
Determined to support innovation across the board in this sector, YCM is now gearing up to host the Monaco Smart & Sustainable Marina Rendezvous on 22-23 September 2024, organised by Monaco Marina Management (M3).
Under the aegis of the collective ‘Monaco, Capital of Advanced Yachting’ initiative, the meeting is supported by Prince Albert II of Monaco Foundation and the Principality’s digital transition programme Extended Monaco, alongside UBS, Sanlorenzo, MB92 Group and Bombardier. “Our main driver of innovation is sustainability and we are delighted to support this event once again this year. Taking part in this meeting of the brightest and boldest minds and witnessing the innovative and tangible solutions that are brought forward give us optimism and confidence to define a new norm for the future” says Emmanuel Bornand, Vice President, International Business Aircraft Sales, Bombardier.
Monaco Smart & Sustainable Marina: an ecosystem driving change in marinas
Organised by Monaco Marina Management (M3), this 4th edition will gather 250+ delegates at the YCM, including entrepreneurs, industrialists, investors, promoters and marina developers from all over the world. An exhibition area provides an opportunity for all to see and test the latest innovations from the selected startups and scaleups.
“Faced with today’s environmental challenges, we firmly believe the key is to put innovators in direct contact with marina operators and other professionals in the sector to get technological solutions in place. Together, thanks to everyone’s expertise, we can create marinas that are models of sustainable excellence,” explains José Marco Casellini, CEO of M3, a Monaco-based consultancy specialising in development, management and promotion of marinas, yacht clubs and sailing schools.
Getting experts to interact via workshops
Three key topics will be debated at workshops: energy transition and sustainability, including greener fuels and waste reduction; building resilient, energy-efficient infrastructure; and diversifying marina services. The main objectives are to encourage collaboration, develop sustainable strategies, and drive the adoption of best practices in sustainable marina management.
Keynote presentations: understanding the challenges
During the meeting there will be three keynote talks exploring how technology, the banking sector and architecture can transform marinas. Discussions will focus on optimising user experience with advanced technologies; the role of financial institutions in the sustainable approach to marinas; and the importance of innovative architecture design to create marinas that are not only efficient and appealing but also respect the environment.
Architecture: call for ideas in eco-sensitive areas
This year, architects and students are invited to submit designs for a floating marina in ecologically sensitive areas. A jury, chaired by the Zaha Hadid Architects firm, alongside Jean-Michel Wilmotte and experts, will assess the projects. The goal is to create avant-garde solutions that respect the environment and meet modern marina demands. The location will be revealed in the coming days.
International Smart & Sustainable Marina Awards: rewarding ecosystem recognition
At the end of two days of exchanges and networking, the International Smart & Sustainable Marina Awards will be presented on Monday 23rd September 2024 at 4.00pm to the winners in three categories: Startups & Scaleups, Marinas, and Architects (professionals & students).
It is through events and initiatives like these that Yacht Club de Monaco maintains its role as leader in innovation, by connecting the whole maritime ecosystem to push for a more sustainable future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724805334/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom